Cargando…

Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation

Peritoneal dissemination is a particular form of metastasis typically observed in ovarian cancer and the major cause for poor patient’s outcome. Identification of the molecular players involved in ovarian cancer dissemination can offer an approach to develop treatment strategies to improve clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coelho, Ricardo, Ricardo, Sara, Amaral, Ana Luísa, Huang, Yen-Lin, Nunes, Mariana, Neves, José Pedro, Mendes, Nuno, López, Mónica Nuñez, Bartosch, Carla, Ferreira, Verónica, Portugal, Raquel, Lopes, José Manuel, Almeida, Raquel, Heinzelmann-Schwarz, Viola, Jacob, Francis, David, Leonor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329842/ https://www.ncbi.nlm.nih.gov/pubmed/32612258 http://dx.doi.org/10.1038/s41389-020-00246-2

Ejemplares similares

Mesothelin Expression Is Not Associated with the Presence of Cancer Stem Cell Markers SOX2 and ALDH1 in Ovarian Cancer
por: Nunes, Mariana, et al.
Publicado: (2022)

Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment
por: Hilliard, Tyvette S., et al.
Publicado: (2021)

Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis
por: Huang, Yen-Lin, et al.
Publicado: (2020)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer
por: Coelho, Ricardo, et al.
Publicado: (2022)

Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers
por: Montavon, Celine, et al.
Publicado: (2018)

The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model
por: Mizukami, Tatsuzo, et al.
Publicado: (2018)

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
por: Fedier, André, et al.
Publicado: (2022)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Disseminated Peritoneal Leiomyomatosis
por: Momtahan, Mozhdeh, et al.
Publicado: (2011)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

A Mouse Intra-Intestinal Infusion Model and its Application to the Study of Nanoparticle Distribution
por: Sadio, Ana, et al.
Publicado: (2016)

Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
por: Zhang, Jingli, et al.
Publicado: (2014)

Detection of isoforms and genomic alterations by high-throughput full-length single-cell RNA sequencing in ovarian cancer
por: Dondi, Arthur, et al.
Publicado: (2023)

High‐grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer
por: Jacob, Francis, et al.
Publicado: (2020)

Near infrared photoimmunotherapy with an anti-mesothelin antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
por: Gubbels, Jennifer AA, et al.
Publicado: (2006)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells
por: Lazzerini, Lea, et al.
Publicado: (2020)

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin
por: Lurie, Eugene, et al.
Publicado: (2020)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

Heart failure as a first sign of disseminated tuberculosis
por: Naia, Leonor, et al.
Publicado: (2021)

Disposition Kinetics of Taxanes in Peritoneal Dissemination
por: Miyamoto, Ken'ichi, et al.
Publicado: (2012)

Characterization of human mesothelin transcripts in ovarian and pancreatic cancer
por: Muminova, Zhanat E, et al.
Publicado: (2004)

Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma
por: Yu, Liping, et al.
Publicado: (2010)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Preoperative Serum Levels of Mesothelin in Patients with Colon Cancer
por: Bostancı, Özgür, et al.
Publicado: (2014)

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
por: Zhao, Xiao-Yan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_22ng4b0osgjkm8u9b2glqtq4kc